Insulet (PODD) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Insulet (PODD) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 12.92% |
| 10 | Insulet | 10.32 Bn | 9.78 Bn | 562.60 Mn | 322.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 322.22% |
| Mar 31, 2026 | 156.62% |
| Dec 31, 2025 | 0.99% |
| Sep 30, 2025 | 13.03% |
| Jun 30, 2025 | -88.07% |
| Mar 31, 2025 | -31.07% |
| Dec 31, 2024 | -2.61% |
| Sep 30, 2024 | 49.33% |
| Jun 30, 2024 | 590.84% |
| Mar 31, 2024 | 116.39% |
| Dec 31, 2023 | 508.24% |
| Sep 30, 2023 | 1,098.08% |
| Jun 30, 2023 | 178.00% |
| Mar 31, 2023 | -14.39% |
| Dec 31, 2022 | -41.78% |
| Sep 30, 2022 | -141.27% |
| Jun 30, 2022 | -40.00% |
| Dec 31, 2021 | 270.76% |
| Sep 30, 2021 | 8.62% |
| Jun 30, 2021 | -273.61% |